News headlines about Flexion Therapeutics (NASDAQ:FLXN) have been trending somewhat positive on Friday, according to Accern Sentiment. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flexion Therapeutics earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.4485329931775 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Flexion Reports Second Quarter 2017 Financial Results and Recent Business Highlights (biospace.com)
- Flexion Therapeutics’ (NASDAQ:FLXN) Buy Rating Reiterated at Needham & Company LLC (americanbankingnews.com)
- Headed For a Pullback? Share Update on Flexion Therapeutics Inc (FLXN) – Sparta Review (spartareview.com)
- Analysts Expect Flexion Therapeutics, Inc. (NASDAQ:FLXN) Will Post Earnings of -$0.92 Per Share (americanbankingnews.com)
- Flexion Therapeutics, Inc. (NASDAQ:FLXN) Announces Quarterly Earnings Results (americanbankingnews.com)
FLXN has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $34.00 target price on shares of Flexion Therapeutics in a research note on Wednesday, April 26th. Zacks Investment Research cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Needham & Company LLC restated a “buy” rating and set a $34.00 price target on shares of Flexion Therapeutics in a research note on Monday, May 15th. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, BMO Capital Markets restated a “buy” rating on shares of Flexion Therapeutics in a research note on Tuesday, June 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $31.30.
Flexion Therapeutics (NASDAQ:FLXN) traded up 4.39% during mid-day trading on Friday, reaching $22.83. 284,919 shares of the company were exchanged. The stock’s market capitalization is $726.59 million. Flexion Therapeutics has a one year low of $15.44 and a one year high of $29.41. The stock has a 50 day moving average of $22.55 and a 200-day moving average of $21.25.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.11. On average, equities analysts expect that Flexion Therapeutics will post ($3.67) earnings per share for the current fiscal year.
In other news, Director Mark Stejbach purchased 1,580 shares of the stock in a transaction on Friday, June 16th. The shares were acquired at an average price of $17.02 per share, with a total value of $26,891.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Michael D. Clayman purchased 5,000 shares of the stock in a transaction on Monday, June 5th. The shares were purchased at an average cost of $17.23 per share, for a total transaction of $86,150.00. Following the acquisition, the insider now directly owns 20,146 shares of the company’s stock, valued at $347,115.58. The disclosure for this purchase can be found here. 15.98% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Flexion Therapeutics (NASDAQ:FLXN) Stock Price” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/11/flexion-therapeutics-nasdaqflxn-earning-somewhat-favorable-media-coverage-analysis-finds-updated.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
What are top analysts saying about Flexion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Flexion Therapeutics Inc. and related companies.